VISTA Protein Identified as Mesothelioma Growth Driver
Researchers have found that targeting this specific protein could slow the growth of aggressive mesothelioma tumors.
Updated on Sept. 28, 2026 in Cancer
Scientists have identified the protein VISTA as a primary driver of cancer cell proliferation in mesothelioma. This finding suggests a new potential therapeutic target for a disease that has historically lacked effective treatment options.
Why it matters
Current therapies for mesothelioma have limited efficacy, making the discovery of a new biological driver critical for developing more targeted treatment strategies. This research establishes a molecular foundation that could eventually guide new clinical approaches.
This preclinical study utilized immunoprecipitation-mass spectrometry, RNA-seq, and mouse xenograft models to analyze mesothelioma cells. The findings confirm that VISTA knockdown effectively suppresses tumor growth in both in vitro and in vivo settings.
The players
British Journal of Cancer
A prominent peer-reviewed medical journal that publishes original research in the field of oncology.
The details
VISTA appears to function by interacting with specific cell adhesion molecules and the RIPK1 pathway, which triggers enhanced AKT phosphorylation. This biological signaling cascade encourages the tumor cells to proliferate more rapidly. By knocking down or inhibiting this protein, researchers were able to interrupt the cellular machinery required for the tumor to expand.
Timeline
September 28, 2026: The study was published in the British Journal of Cancer.
Health Landscape
This research expands the current focus on immune-related proteins in thoracic cancers by identifying VISTA as a distinct therapeutic target. It follows the precedent of targeting tumor-intrinsic pathways to address the limitations of existing systemic cancer treatments.
While this laboratory research does not change current care, it represents an important shift in how scientists approach mesothelioma treatment. Patients should consult with their oncology team to understand how new, targeted therapies under development may fit into their future care plans.
The takeaway
The discovery that VISTA drives tumor growth highlights the importance of protein-specific targeting in mesothelioma. Discuss with your physician whether clinical trials for emerging molecular therapies are appropriate as you manage your treatment plan.
Further reading
For more information on current treatment paradigms, visit the Cancer section.
More information
View the complete study on mesothelioma cell proliferation to learn more about the methodology.
Source note: This article includes information reported by Nature.
